- Pharmaceutical companies
- Novo Nordisk
Novo Nordisk
Phone: +355 4 225 3522
Fax: +355 4 2253 554
E-mail: infoal@novonordisk.com
Web: https://www.novonordisk.al
Type | Aktieselskab |
---|---|
Traded as | |
Industry | Pharmaceuticals, Health care |
Founded | December 21, 1923 (1923-12-21) |
Headquarters | Novo Allé, DK-2880, Bagsværd, Denmark |
Key people | Helge Lund (Chairman) Lars Fruergaard Jørgensen (President & CEO) |
Products | Ozempic, Ryzodeg, Victoza, NovoEight, Activella, Novolin, Levemir, NovoSeven, Norditropin, Tresiba, Xultophy, NovoRapid, Fiasp, Saxenda |
Revenue | 140.8 billion kr. (2021) |
Operating income | 58.64 billion kr. (2021) |
Net income | 47.76 billion kr. (2021) |
Total assets | 194.5 billion kr. (2021) |
Total equity | 70.75 billion kr. (2021) |
Number of employees | 48,478 (end 2021) |
Website | novonordisk.com |
We are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 43,000 people in 80 offices around the world, and market our products in 170 countries.
For detailed contact information visit location pages below.
Novo Nordisk's locations around the world
Europe
North America
Asia
Africa
Oceania
Clinical Trials sponsored by Novo Nordisk
-
Novo Nordisk A/S招聘中2型糖尿病美国, 塞尔维亚, 意大利, 波兰, 中国, 匈牙利, 沙特阿拉伯
-
Novo Nordisk A/S招聘中转甲状腺素蛋白淀粉样变性心肌病 (ATTR CM)美国, 荷兰, 德国, 加拿大, 捷克语, 法国, 意大利, 葡萄牙, 西班牙
-
Novo Nordisk A/S招聘中2型糖尿病美国, 台湾, 澳大利亚, 匈牙利, 德国, 印度, 加拿大, 西班牙, 捷克语, 阿根廷, 波兰, 哥伦比亚, 南非, 法国, 希腊, 罗马尼亚
-
Novo Nordisk A/S招聘中心脏衰竭 | 全身性炎症美国, 希腊, 法国, 澳大利亚, 捷克语, 西班牙, 印度, 加拿大, 火鸡, 葡萄牙, 马来西亚, 波兰, 英国, 德国, 保加利亚, 阿根廷
-
Novo Nordisk A/S招聘中肥胖 | 2型糖尿病 | 慢性肾病美国, 西班牙, 泰国, 印度, 法国, 波兰, 加拿大, 日本, 希腊, 匈牙利, 阿根廷, 巴西, 斯洛伐克